Hub

U.S. healthcare system hub

The U.S. healthcare system is fragmented, payer-driven, and difficult to understand without separating insurance, providers, coding, coverage, and reimbursement.

Glossary Source methodology Sitemap

1Start with structureRead the overview before specialized pages.

2Use comparisons carefullySimilar words often describe different institutions.

3Check maintenance markersRegulatory and payment pages change more quickly.

4Follow internal linksThe site is designed as a reference graph.

Core pages

Recommended starting points

These pages define the cluster and point to more specialized pages as the site build expands.

Core system

U.S. healthcare overview

The U.S. system explained for international readers.

Financing

Health insurance

Medicare, Medicaid, employer-sponsored insurance, and commercial coverage.

Payment

Coding and reimbursement

The practical route from service to payment.

Cluster index

Current foundation links

Start HereReader orientation GlossaryTerms Source MethodologySources SitemapFull index 2012 ArchiveHistorical material Editorial StandardsMaintenance rules

U.S. system foundation layer

U.S. healthcare system, payer, provider, and access pages

These pages explain the fragmented U.S. payer and provider system for readers comparing it with China.

U.S.-China comparison layer

Researched U.S.-China comparison pages

These pages compare the institutional mechanisms that drive access, payment, provider behavior, technology adoption, and regulation in the two systems.

U.S. vs. China Healthcare Systemsystem architecture comparison U.S. vs. China Health Insuranceinsurance architecture and financial protection comparison U.S. vs. China Hospitalshospital role, ownership, hierarchy, and patient behavior U.S. vs. China Primary Caregatekeeping, community care, and first-contact access U.S. vs. China Rural Healthcarerural access with different institutional causes U.S. vs. China Urban Healthcareurban concentration and navigation problem U.S. vs. China Public Healthpublic-health administration and state capacity U.S. vs. China Aging and Healthcareaging pressure, family structure, and financing U.S. vs. China Long-Term Carelong-term care financing and delivery U.S. vs. China Physician Workforcetraining, compensation, status, and practice environment U.S. vs. China Nursing Workforcenursing supply, role, and staffing context U.S. vs. China Medical Educationmedical training, licensing, and career pathway U.S. vs. China Hospital PaymentDRGs, FFS, budgets, payer contracts, and incentives U.S. vs. China Drug PricingPBMs, Medicare, NRDL, VBP, and negotiation U.S. vs. China Medical Device Pricinghospital purchasing, GPOs, VBP, and value analysis U.S. vs. China Reimbursementpayment pathways for products and services U.S. vs. China Health Technologyadoption environment for digital health and medtech U.S. vs. China Telehealthtelehealth regulation, payment, and adoption patterns U.S. vs. China Healthcare Data PrivacyHIPAA versus PIPL and data-security context U.S. vs. China AI Governance in Healthcaremedical AI regulation, data governance, and adoption

Regulatory strategy layer

Regulation, approval, trials, and postmarket governance pages

These pages analyze FDA and NMPA pathways, drug and device approval, clinical trials, real-world evidence, postmarket surveillance, software, cybersecurity, and regulatory localization.

FDA vs. NMPAregulator mandate and institutional operating model Drug Approval in the United States and Chinadrug evidence, review, and market-access sequencing Medical Device Approval in the United States and Chinaclassification, risk, evidence, and route-to-market Diagnostics Approval in the United States and ChinaIVD, laboratory, and clinical-use pathway Digital Therapeutics Regulation in the U.S. and Chinasoftware claims, clinical evidence, and payment uncertainty AI Medical Device Regulation in the U.S. and ChinaAI-enabled SaMD, lifecycle change, validation, and safety Clinical Trials in the U.S. and Chinatrial authorization, sites, ethics, and evidence transferability Human Subjects Research in Chinaethics, consent, institution, and participant protection Good Clinical Practice in Chinaclinical trial quality system Ethics Committees in Chinainstitutional research gatekeeper Postmarket Surveillance in Chinapost-approval safety and lifecycle control Pharmacovigilance in Chinadrug safety monitoring and risk management Medical Device Adverse Event Reporting in Chinadevice safety signal and corrective action Real-World Evidence in Chinaevidence beyond traditional trials Accelerated Approval Pathways in Chinapriority, breakthrough, conditional, and urgent-need review Breakthrough Medical Device Pathways in the U.S. and Chinaexpedited medtech review and market implications Companion Diagnostics in the U.S. and Chinadrug-diagnostic co-development and access Software as a Medical Device in Chinasoftware classification, registration, and lifecycle control Cybersecurity for Medical Devices in Chinadevice safety, data security, and network risk Regulatory Localization in Chinamarket-entry playbook for adapting global regulatory strategy

China-to-U.S. market-entry layer

Chinese healthcare companies entering the U.S.

These pages analyze U.S. entry through FDA readiness, reimbursement, CPT and HCPCS coding, coverage, payer evidence, hospital value analysis, distributors, sales teams, KOLs, investor trust, privacy, localization, postmarket support, liability, and common mistakes.

Chinese Healthcare Companies Entering the U.S.canonical China-to-U.S. healthcare market entry playbook Chinese Medtech Companies Entering the U.S.medtech-specific U.S. route from FDA to reimbursement and sales Chinese Biopharma Companies Entering the U.S.biopharma path through FDA, trials, payer evidence, and commercialization FDA Readiness for Chinese Healthcare Companiesregulatory preparedness decision matrix U.S. Reimbursement Readiness for Chinese Companiescoding, coverage, payment, and economic evidence readiness CPT and HCPCS Coding for Chinese Healthcare Companiescode pathways without drowning readers in coding minutiae U.S. Coverage Strategy for Healthcare Productscommercial, Medicare, and Medicaid coverage strategy Payer Evidence for U.S. Market Entryevidence standards for payer and coverage decisions Hospital Value Analysis Committeeshospital adoption gate for devices and supplies U.S. Distributor Strategy for Chinese Medtechchannel design and distributor risk in the U.S. Building a U.S. Sales Organization in Healthcarewhen direct sales makes sense and what it requires U.S. Clinical KOL Strategyclinical credibility-building in U.S. hospitals and specialties U.S. Investor Readiness for Chinese Healthcare Companiesinvestor diligence expectations, trust, and evidence Brand Trust for Chinese Healthcare Companies in the U.S.trust barriers, evidence, service, and geopolitical context U.S. Health Data Privacy for Chinese CompaniesHIPAA and data governance for Chinese entrants Product Localization for the U.S. Healthcare Marketworkflow, evidence, support, documentation, and service localization Postmarket Support in the U.S. Healthcare Marketservice, quality systems, complaints, and adoption durability Product Liability and Litigation Risk in U.S. Healthcarehigh-level risk page for foreign entrants U.S. Reimbursement Pitfalls for Foreign Healthcare Companiesapproval versus payment misunderstandings Common Mistakes Chinese Healthcare Companies Make in the U.S.Chinese-company-specific market-entry pitfalls

Simplified Chinese access layer

中文美国医疗体系与市场进入页面

These simplified Chinese pages explain U.S. healthcare structure, insurance, coding, coverage, reimbursement, FDA/NMPA differences, U.S. commercialization, payer evidence, and common entry mistakes.

中美医疗体系与跨境医疗战略指南选择性入口页 美国医疗体系如何运作美国体系结构说明 美国医保结构多支付方结构 Medicare 是什么Medicare 术语解释 Medicaid 是什么Medicaid 术语解释 美国商业医疗保险商业保险与雇主保险 美国医疗编码、覆盖和报销Coding、Coverage、Reimbursement 三段式 FDA 与 NMPA 的区别FDA 与 NMPA 比较 美国医疗器械商业化路径医疗器械从 FDA 到医院采用 中国医疗器械企业进入美国市场中国器械企业赴美路径 中国生物医药企业进入美国市场中国生物医药赴美路径 美国医疗报销机制支付而非患者报销 美国医院采购机制医院采购、GPO 与价值分析 美国支付方证据要求支付方证据 中国企业进入美国医疗市场的常见误区误区与修正 美国医疗体系常用术语中英对照中英术语入口页 CPT 是什么CPT 编码解释 HCPCS 是什么HCPCS 编码解释 Coverage 和 Reimbursement 的区别覆盖与报销区别 Prior Authorization 是什么事先授权与使用管理

Simplified Chinese reference layer

中文 FAQ、路径图、数据参考、术语表和检查清单

These pages add Chinese-language FAQs, FDA pathway explanations, executive briefs, U.S. cost and insurance data references, payment/regulatory/insurance glossaries, and market-entry checklists.

美国医疗体系常见问题中文读者常见误解 FDA 医疗器械路径图510(k)、De Novo、PMA 路径图 进入美国医疗市场高管简报中国企业美国市场进入摘要 中美医疗体系主要区别面向中文读者的制度差异 美国支付与报销术语表中英支付术语桥 美国监管术语表FDA 术语桥 美国医保术语表美国医保词汇桥 美国医疗成本数据参考美国医疗支出基准 美国医保覆盖数据参考美国保险覆盖结构数据 FDA 批准不等于美国市场成功FDA 之后的商业化门槛 ICD-10 是什么诊断编码 DRG 是什么住院支付分组 PBM 是什么药品福利管理 Value Analysis Committee 是什么医院价值分析委员会 Clinical Evidence 是什么临床证据的多重用途 Real-World Evidence 是什么真实世界证据 CPT Category III 代码是什么新兴技术临时代码 Medicare Coverage 是什么Medicare 覆盖判断 美国医院 Value Analysis 路径图从医生兴趣到采购批准 中国企业美国市场进入检查清单进入美国市场前的准备度评估